Comparison of prognostic impact of chromosome 1q21 gain in
patients with multiple myeloma treated by Velcade, thalidomide
and any conventional therapy

D 2007

Comparison of prognostic impact of chromosome 1q21 gain in patients with multiple myeloma treated by Velcade, thalidomide and any conventional therapy

NĚMEC, Pavel, Henrieta GREŠLIKOVÁ, Romana ZAORALOVÁ, Hana FILKOVÁ, Vladimíra VRANOVÁ et. al.

Základní údaje

Originální název

Comparison of prognostic impact of chromosome 1q21 gain in patients with multiple myeloma treated by Velcade, thalidomide and any conventional therapy

Název česky

Srovnání prognostického významu amplifikace 1q21 u pacientů s mnohočetným myelomem léčených Velcade, thalidomidem a konvenční chemoterapií

Autoři

NĚMEC, Pavel (203 Česká republika), Henrieta GREŠLIKOVÁ (703 Slovensko), Romana ZAORALOVÁ (203 Česká republika), Hana FILKOVÁ (203 Česká republika), Vladimíra VRANOVÁ (703 Slovensko), Renata KUPSKÁ (203 Česká republika), Jana SMEJKALOVÁ (203 Česká republika), Alexandra OLTOVÁ (203 Česká republika), Petr KUGLÍK (203 Česká republika) a Roman HÁJEK (203 Česká republika, garant)

Vydání

Volume 92, supplement no.1. Pavia, Italy, Hematologica/The Hematology Journal, od s. 49-49, 1 s. 2007

Nakladatel

Ferrata-Storti Foundation

Další údaje

Jazyk

angličtina

Typ výsledku

Stať ve sborníku

Obor

Genetika a molekulární biologie

Stát vydavatele

Itálie

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 5.516

Kód RIV

RIV/00216224:14110/07:00022794

Organizační jednotka

Lékařská fakulta

ISSN

UT WoS

000247176900138

Klíčová slova anglicky

multiple myeloma; 1q21 gain; Velcade; thalidomide; fluorescence in situ hybridisation

Štítky

1q21 gain, fluorescence in situ hybridisation, multiple myeloma, Thalidomide, Velcade

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 19. 3. 2009 11:04, Mgr. Pavel Němec, Ph.D.

Anotace

ORIG CZ

V originále

Background Amplification of chromosome band 1q21 as well as increased expression of CKS1B gene in this area is a frequently mentioned prognostic factor for patients with multiple myeloma (MM). Aims This study was aimed at comparison of prognostic impact of 1q21 gain in three selected groups of patients with diagnosed MM based on treatment regiment. Methods Plasma cells were identified by cytoplasmic light-chain fluorescence in situ hybridisation (cIg-FISH), 1q21 amplification (Amp1q21) utilizing the 1q21/1p36 DNA probe. Amp1q21 was taken such as detection of one or more additional signals of 1q21 DNA probe. Cut-off level for Amp1q21 was established to 20% of total amount of cells with additional signals detected. Patients with Amp1q21 and patients lacking Amp1q21 of each group were statistically correlated with clinical parameters. Up to date we have carried out analysis of 66 (n=66) patients. This group of patients with median of follow up 8,6 months (range: 0,3-30,4) was divided according to the undergone therapy into 3 groups: "C-group" comprises 17 samples of patients treated by any conventional therapy; "T-group" comprises 27 samples of patients treated by thalidomide; "V-group" comprises 22 samples of patients treated by Velcade. The response and other parameters such as time to progression (TTP) and overall survival (OS) were assigned by IMWG criteria. Results Amp1q21 was found in 62.1% of all 66 patients. Percentage of patients with Amp1q21 in C/T/V-groups were as follows: 64.7% / 40.7% / 86.4%, respectively. Clinical parameters valid for patients with Amp1q21 (listed in C/T/V order) were as follows: overall response rate (ORR) 42.8% / 83.3% / 50%; TTP 8.8 / 12.1 / 8.0 months; OS 16.1 / 6.6 / not yet reached for V-group. The same parameters valid for patients lacking Amp1q21: ORR 33.3% / 80% / 66.7%; TTP not yet reached for C-group / 8.2 / not yet reached for V-group; OS not yet reached for all groups. TTP median of patients with Amp1q21 vs. patients lacking 1q21 was: 8.2 vs. 12.1 months (p=0.269), OS 6.6 vs. not yet reached (p=0,072) in thalidomide group. We didn't find any other significant differences between patients with / without Amp1q21 and their parameters in V- and C-group. Summary / Conclusions Our results suggest that patients with Amp1q21 treated by thalidomide show a trend towards the worst prognosis based on overall survival. We are currently investigating whether or not our findings will be confirmed on a larger cohort of patients with longer follow-up. Supported by Monoclonal Gammopathy and Multiple Myeloma Basic Research Centre (LC 06027), Masaryk University, Czech republic.

Česky

Práce pojednává o významu amplifikace 1q21 u pacientů s mnohočetným myelomem léčených Velcade, thalidomidem či konvenční chemoterapií.

Návaznosti

LC06027, projekt VaV

Název: Univerzitní výzkumné centrum - Česká myelomová skupina (Akronym: LC MGUS)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Univerzitní výzkumné centrum - Česká myelomová skupina (URC - CMG)

Citovat

NĚMEC, Pavel, Henrieta GREŠLIKOVÁ, Romana ZAORALOVÁ, Hana FILKOVÁ, Vladimíra VRANOVÁ, Renata KUPSKÁ, Jana SMEJKALOVÁ, Alexandra OLTOVÁ, Petr KUGLÍK a Roman HÁJEK. Comparison of prognostic impact of chromosome 1q21 gain in patients with multiple myeloma treated by Velcade, thalidomide and any conventional therapy. In Hematologica/The Hematology Journal. Volume 92, supplement no.1. Pavia, Italy: Ferrata-Storti Foundation, 2007, s. 49-49. ISSN 0390-6078.

@inproceedings{726961,
   author = {Němec, Pavel and Grešliková, Henrieta and Zaoralová, Romana and Filková, Hana and Vranová, Vladimíra and Kupská, Renata and Smejkalová, Jana and Oltová, Alexandra and Kuglík, Petr and Hájek, Roman},
   address = {Pavia, Italy},
   booktitle = {Hematologica/The Hematology Journal},
   edition = {Volume 92, supplement no.1},
   keywords = {multiple myeloma; 1q21 gain; Velcade; thalidomide; fluorescence in situ hybridisation},
   language = {eng},
   location = {Pavia, Italy},
   pages = {49-49},
   publisher = {Ferrata-Storti Foundation},
   title = {Comparison of prognostic impact of chromosome 1q21 gain in patients with multiple myeloma treated by Velcade, thalidomide and any conventional therapy},
   year = {2007}
}

TY  - JOUR
ID  - 726961
AU  - Němec, Pavel - Grešliková, Henrieta - Zaoralová, Romana - Filková, Hana - Vranová, Vladimíra - Kupská, Renata - Smejkalová, Jana - Oltová, Alexandra - Kuglík, Petr - Hájek, Roman
PY  - 2007
TI  - Comparison of prognostic impact of chromosome 1q21 gain in patients with multiple myeloma treated by Velcade, thalidomide and any conventional therapy
PB  - Ferrata-Storti Foundation
CY  - Pavia, Italy
KW  - multiple myeloma
KW  - 1q21 gain
KW  - Velcade
KW  - thalidomide
KW  - fluorescence in situ hybridisation
N2  - Background Amplification of chromosome band 1q21 as well as increased expression of CKS1B gene in this area is a frequently mentioned prognostic factor for patients with multiple myeloma (MM). Aims This study was aimed at comparison of prognostic impact of 1q21 gain in three selected groups of patients with diagnosed MM based on treatment regiment. Methods Plasma cells were identified by cytoplasmic light-chain fluorescence in situ hybridisation (cIg-FISH), 1q21 amplification (Amp1q21) utilizing the 1q21/1p36 DNA probe. Amp1q21 was taken such as detection of one or more additional signals of 1q21 DNA probe. Cut-off level for Amp1q21 was established to 20% of total amount of cells with additional signals detected. Patients with Amp1q21 and patients lacking Amp1q21 of each group were statistically correlated with clinical parameters. Up to date we have carried out analysis of 66 (n=66) patients. This group of patients with median of follow up 8,6 months (range: 0,3-30,4) was divided according to the undergone therapy into 3 groups: "C-group" comprises 17 samples of patients treated by any conventional therapy; "T-group" comprises 27 samples of patients treated by thalidomide; "V-group" comprises 22 samples of patients treated by Velcade. The response and other parameters such as time to progression (TTP) and overall survival (OS) were assigned by IMWG criteria. Results Amp1q21 was found in 62.1% of all 66 patients. Percentage of patients with Amp1q21 in C/T/V-groups were as follows: 64.7% / 40.7% / 86.4%, respectively. Clinical parameters valid for patients with Amp1q21 (listed in C/T/V order) were as follows: overall response rate (ORR) 42.8% / 83.3% / 50%; TTP 8.8 / 12.1 / 8.0 months; OS 16.1 / 6.6 / not yet reached for V-group. The same parameters valid for patients lacking Amp1q21: ORR 33.3% / 80% / 66.7%; TTP not yet reached for C-group / 8.2 / not yet reached for V-group; OS not yet reached for all groups. TTP median of patients with Amp1q21 vs. patients lacking 1q21 was: 8.2 vs. 12.1 months (p=0.269), OS 6.6 vs. not yet reached (p=0,072) in thalidomide group. We didn't find any other significant differences between patients with / without Amp1q21 and their parameters in V- and C-group. Summary / Conclusions Our results suggest that patients with Amp1q21 treated by thalidomide show a trend towards the worst prognosis based on overall survival. We are currently investigating whether or not our findings will be confirmed on a larger cohort of patients with longer follow-up. Supported by Monoclonal Gammopathy and Multiple Myeloma Basic Research Centre (LC 06027), Masaryk University, Czech republic.
ER  -

NĚMEC, Pavel, Henrieta GREŠLIKOVÁ, Romana ZAORALOVÁ, Hana FILKOVÁ, Vladimíra VRANOVÁ, Renata KUPSKÁ, Jana SMEJKALOVÁ, Alexandra OLTOVÁ, Petr KUGLÍK a Roman HÁJEK. Comparison of prognostic impact of chromosome 1q21 gain in patients with multiple myeloma treated by Velcade, thalidomide and any conventional therapy. In \textit{Hematologica/The Hematology Journal}. Volume 92, supplement no.1. Pavia, Italy: Ferrata-Storti Foundation, 2007, s.~49-49. ISSN~0390-6078.

Podrobný výpis o publikaci